Latest News
Could you spare about 2hrs helping us understand Cancer Related Cognitive Impairment or ‘Brain Fog’?
WHY: To see if the brain changes in those who have cancer or get treatment.
WHO: Women who have just received a breast cancer diagnosis AND women who are healthy and want to help.
WHAT is involved: Having two brain scans in a MRI scanner and completing three questionnaires. The scans will be at different times (for patients one before your surgery and one after your first chemotherapy).
HOW LONG: Each visit to the MRI scanner will last up to 1.5 hours. 50mins of this will be the brain scan.
WHERE: The University of Auckland Centre for Advanced Magnetic Resonance Imaging (CAMRI) 85 Park Road, Grafton, Auckland (parking arranged).
Pharmac’s announcement that they will fund the breakthrough medicine Enhertu (trastuzumab deruxtecan, T-DXd) from 1st January 2025 for advanced HER2 positive breast cancer (HER2+ ABC) is fantastic news.
Libby Burgess, chair of BCAC, says: “We’re delighted to see this vital medicine funded given the outstanding results from clinical trials showing that Enhertu keeps the cancer stable for four times as long as the previous best treatment and increases length of life. We’re very pleased that Pharmac has listened to our feedback on its consultation and extended funding to include those whose cancer has already advanced on Kadcyla and to allow those who have unmanageable side effects with Enhertu to be treated with Kadcyla. The decision to fund will enable women and their families to…
Chair Libby Burgess and Secretary Fay Sowerby recently delivered BCAC’s 2024 Ministerial Briefing to Hon. Dr Shane Reti, Minister of Health. The briefing identifies priority areas for action to improve breast cancer outcomes. (You can read the full briefing by clicking here). Libby and Fay also met with Hon. Dr Ayesha Verrall (Labour) and MP Todd Stephenson (ACT) to discuss the briefing in detail, and it was copied to politicians with an interest in health and technology from all parties.
Over the last 25 years, BreastScreen Aotearoa (BSA) has provided more than 5 million free screening mammograms to New Zealand women. BCAC is pleased to see BSA celebrating this milestone and we encourage all eligible women to take advantage of the national screening programme. All women aged between 45 and 69 are entitled to a free mammogram every two years. Click here to learn more about the programme and to enrol, or phone 0800 270 200. Regular breast screening with a mammogram saves lives by finding breast cancer early, when treatment is more likely to cure the cancer.
International Metastatic (Advanced) Breast Cancer Day was celebrated in style with the Auckland Harbour Bridge bathed in blue, green and pink lights. Sweet Louise, a charity dedicated to supporting New Zealanders with metastatic breast cancer (MBC), hosted an event at the Royal NZ Yacht Squadron, the perfect venue to enjoy the lights on the bridge. The day is marked around the world with iconic monuments and buildings lit in the MBC colours of green for hope and renewal, blue for healing and spirituality and pink, the traditional breast cancer colour, #LightUpMBC.
If you have had axillary (armpit) lymph nodes removed during breast surgery, you may have been told that you should avoid any medical procedures involving needles on the affected arm. This traditional advice was based on the idea that using needles on this arm might increase the risk of lymphoedema. However, the Australian and New Zealand College of Anaesthetists have recently changed that recommendation, saying that clinical evidence shows that this is not the case and that the arm of the affected side can usually be safely used for medical procedures. In fact, they say, using the arm on the affected side can be better for patient safety and comfort.
It’s wonderful news for those with HER2 positive (HER2+) advanced breast cancer (ABC) that Pharmac proposes to fund Enhertu (trastuzumab deruxtecan, T-DXd), a breakthrough HER2-targeted medicine, from 1st January 2025.
Enhertu has been shown to keep HER2+ ABC disease stable four times longer than current treatments, and results in a longer survival time. This time is precious for New Zealand women with breast cancer and we’re delighted to see that Enhertu will be funded.
One of the biggest challenges in any diagnosis, and treatment journey, is finding positivity during very worrying and difficult times.
It’s easy to be afraid and get stuck in a negative spiral. Being positive and thinking positively can help you cope with cancer, but it is natural to also feel upset and frightened sometimes. People with cancer are often encouraged to be positive. But it’s not always easy. It’s important to acknowledge there will be some very difficult days and allow ourselves to feel and express emotion.
If positivity doesn't feel right for you, or doesn't feel right in a specific situation, or on any given day, that's okay. Acknowledge how you’re feeling, allow it to be, and then think about some actions you might take to feel differently.
BCAC recently joined over twenty groups representing New Zealanders with a wide range of diseases to visit Wellington under the Patient Voice Aotearoa (PVA) banner. We met Hon. Dr Ayesha Verrall, Labour’s health spokesperson and former Health Minister, and visited Pharmac to hear Hon. David Seymour, Associate Health Minister (Pharmac) present his Letter of Expectation to Hon. Paula Bennett, Pharmac’s recently appointed Board Chair.
Good news for New Zealanders with advanced triple negative breast cancer. From 1st October 2024 Pharmac will fund Keytruda (pembrolizumab) for those with recurrent or metastatic triple negative breast cancer. Around 15% of all breast cancers, and 16% of metastatic breast cancers, are classified as triple negative. This type of breast cancer does not respond to medicines that target HER2 or oestrogen receptors and until now only chemotherapy was available for these patients in our public system. Keytruda is an immunotherapy that is expected to improve progression-free survival, overall survival and quality of life for people with triple negative breast cancer who have a PD-L1 Combined Positive Score ≥10.
